11
IRUS TotalDownloads
Altmetric
Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing
File | Description | Size | Format | |
---|---|---|---|---|
COVID Bacteria RR _ MASTER _ CID _ FINAL _ Revised _ clean.docx | Accepted version | 171.09 kB | Microsoft Word | View/Open |
Title: | Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing |
Authors: | Rawson, TM Moore, L Zhu, N Ranganathan, N Skolimowska, K Gilchrist, M Satta, G Cooke, G Holmes, A |
Item Type: | Journal Article |
Abstract: | Background To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. Methods MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. Results 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus. For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described. For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. Conclusions Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required. |
Issue Date: | 2-May-2020 |
Date of Acceptance: | 30-Apr-2020 |
URI: | http://hdl.handle.net/10044/1/78679 |
DOI: | 10.1093/cid/ciaa530 |
ISSN: | 1058-4838 |
Publisher: | Oxford University Press (OUP) |
Start Page: | 2459 |
End Page: | 2468 |
Journal / Book Title: | Clinical Infectious Diseases |
Volume: | 71 |
Issue: | 9 |
Copyright Statement: | © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model). This is a pre-copy-editing, author-produced version of an article accepted for publication in Clinical Infectious Diseases following peer review. The definitive publisher-authenticated version Timothy M Rawson, Luke S P Moore, Nina Zhu, Nishanthy Ranganathan, Keira Skolimowska, Mark Gilchrist, Giovanni Satta, Graham Cooke, Alison Holmes, Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing, Clinical Infectious Diseases, , ciaa530, is available online at: https://doi.org/10.1093/cid/ciaa530 |
Sponsor/Funder: | National Institute for Health Research National Institute for Health Research |
Funder's Grant Number: | HPRU-2012-10047 HPRU-2012-10047 |
Keywords: | Science & Technology Life Sciences & Biomedicine Immunology Infectious Diseases Microbiology SARS-CoV-2 antimicrobial stewardship antimicrobial resistance ACUTE RESPIRATORY SYNDROME INTRAVENOUS ANTIBIOTICS INFECTION PNEUMONIA SARS-CoV-2 antimicrobial resistance antimicrobial stewardship Anti-Infective Agents Antimicrobial Stewardship Bacterial Infections COVID-19 Coinfection Drug Resistance, Microbial Humans Mycoses SARS-CoV-2 Humans Bacterial Infections Mycoses Anti-Infective Agents Drug Resistance, Microbial Coinfection Antimicrobial Stewardship COVID-19 SARS-CoV-2 Microbiology 06 Biological Sciences 11 Medical and Health Sciences |
Publication Status: | Published |
Online Publication Date: | 2020-05-02 |
Appears in Collections: | Department of Infectious Diseases Faculty of Medicine Imperial College London COVID-19 |